ClinicalTrials.gg
CompletedNCT06714825Updated Dec 30, 2025

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics in Overweight/Obese Healthy Subjects

A Phase 1 interventional study of HS235 and Placebo in Overweight and Obesity, sponsored by 35Pharma Inc. Completed at 1 site in Canada. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-30.

Primary conditionObesityRegistry: OverweightReclassifiedWhy we changed it
Registry
Overweight — the first condition term the registry derived for this study.
ClinicalTrials.gg
Obesity
Why
  1. The study's listed conditions name Obesity, a narrower term within Overweight.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by 35Pharma Inc · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
39
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 574 studies in Obesity with a site in Canada — 101 open to participants now, 150 under way, 46 of them phase 3. Obesity · Canada.

Enrollment
342nd of 479
39 · median 73
Started
2024
with 26 others
Phase 1
22 of 574
5 open now
Registered
480th of 574
by date

Among the 574 studies in Obesity with a site in Canada, this one is the 342nd largest by enrollment of the 479 interventional ones that give a count, is one of 27 that started in 2024, is one of 22 in phase 1, and was the 480th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

101 of the 574 studies in Obesity with a site in Canada are open now. Recruiting first, the newest first:

96 more — sign in →

All 101 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 40 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 574 studies in Obesity with a site in Canada, or all of them as a file.
02

Study summary

Study of HS235 for Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects

Read the detailed description

A Phase 1 Study Assessing the Pharmacokinetics, Safety, and Pharmacodynamics of HS235 in Overweight and Obese Otherwise Healthy Subjects: Single Ascending Dose (SAD) in Males and Postmenopausal Females and Multiple Ascending Dose (MAD) in Males and Females of Non-childbearing Potential

03

Conditions studied

  • Overweight and Obesity

Browse trials for

04

In context

Obesity Reclassified

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

This study's enrollment of 39 is below the median of 67 across 9,023 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

35Pharma Inc is the lead sponsor of 3 studies on the registry; none are open to participants now.

Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female above 40 years of age, inclusive.
  2. (BMI) between 28 and 40 kg/m2, inclusive.
  3. Body weight at or below 140 kg with a stable body weight.
  4. In good health or with no medical conditions
  5. Females who are or are of Non-child bearing Potential.
  6. Male subjects must be willing not to donate sperm for 90 days after the last dose.
  7. Able to understand the study procedures and provide signed to participate in the study.

Exclusion criteria

Exclusion Criteria:

  1. Females with a positive pregnancy test or who are lactating.
  2. Subjects with diabetes or have previous history of diabetes.
  3. Subjects who have recently donated blood, plasma and .
  4. Subjects with history of alcoholism or drug abuse.
  5. Subjects who received systemic or topical medications, depot injections or implants, hormone replacement, non-prescribed medication or herbal remedies, or daily for > 1 month in previous year.
  6. Subjects with abnormal pulse or blood pressure or temperature.
  7. Subjects with a history of a clinically significant medical disorder or lab abnormality.
  8. Subjects with a significant history of multiple drug allergies, including infusion reactions and to any of the of HS235.
  9. Subjects who are carriers of the surface antigen (HBsAg) and are carriers of the antibody (except if Polymerase Chain Reaction Ribonucleic acid (PCR RNA) is negative); or have a positive result to the test for (HIV) antigen or antibody.
  10. Subjects who have, in the opinion of the Investigator, an abnormality in the echocardiogram or 12-lead that put them at increased risk during the study.
  11. Current or history of treatment with medications that may cause significant weight gain or loss, within 3 months or 5 half-lives of screening.
  12. Obesity induced by other endocrine disorders.
  13. Previous surgical treatment for obesity.
  14. Current or history of treatment with medications that may cause significant weight gain or loss.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

06

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
39 participants (actual)

Study arms

  • Experimental
    Investigational Product

    HS235 Subcutaneous Injection

    Biological: HS235

  • Placebo comparator
    Placebo

    Subcutaneous Injection

    Drug: Placebo

Interventions

  • BiologicalHS235

    Up to 4 Single and 3 Multiple Ascending Doses

  • DrugPlacebo

    Subcutaneous Injection

07

What researchers measure

Primary outcomes

  1. Incidence and Number of Adverse Events (AEs)

    An AE is any untoward medical occurrence in a patient or clinical trial patient administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.The incidence and number of patients who experience an AE will be reported.

    Time frame: up to 106 days for Single dose and 147 days for multiple doses

Secondary outcomes

  1. Area under concentration time curve (AUC) zero to t

    Blood samples will be collected to determine the Area under the concentration-time curve from time zero until the last observed concentration

    Time frame: up to 106 days for Single dose and 147 days for multiple doses

  2. Area under concentration time curve (AUC) zero-infinity

    Blood samples will be collected to determine the Area under the concentration-time curve from time zero to infinity (extrapolated)

    Time frame: up to 106 days for Single dose and 147 days for multiple doses

  3. Maximum observed Plasma Concentration (Cmax)

    Blood samples will be collected to determine Cmax

    Time frame: up to 106 days for Single dose and 147 days for multiple doses

  4. Time to maximum concentration (Tmax)

    Blood samples will be collected to determine Tmax

    Time frame: up to 106 days for Single dose and 147 days for multiple doses

08

Study locations

1 site
  • Syneos Clinical Research Unit
    Québec, Quebec, Canada
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2024 to primary completion in Dec 2025, 12 months.

Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 12 months is above that.

Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 27, 2024
First posted
Dec 4, 2024
StartActual
Nov 28, 2024
Primary completionActual
Dec 2, 2025
CompletionActual
Dec 2, 2025
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06714825
Lead sponsor
35Pharma Inc
Responsible party
Sponsor
First posted
Dec 4, 2024
Start date
Nov 28, 2024
Primary completion
Dec 2, 2025
Completion
Dec 2, 2025
Last update
Dec 30, 2025

Study contacts

Monique Champagne, M.Sc.
study director · VP, Clinical Operations

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HS235

Start the discussion